Jardiance and Atorvastatin Interaction: What the Evidence Actually Shows

Can you take Jardiance and atorvastatin together?

There is no pharmacokinetic mechanism by which empagliflozin would be expected to raise or lower atorvastatin levels, or vice versa. Empagliflozin's clearance depends mainly on UGT2B7, UGT1A3, UGT1A8, and UGT1A9 glucuronidation, while atorvastatin depends mainly on CYP3A4. Because these pathways do not overlap in a way that changes either drug's exposure, the FDA-approved prescribing information for each drug does not list the other as a contraindicated or precautioned combination. This is a mechanism-based and label-based conclusion. A dedicated randomized pharmacokinetic study pairing empagliflozin specifically with atorvastatin (as opposed to other statins or other comparator drugs) was not identified in the sources reviewed for this article, so if a reader needs a citable trial number for that specific pairing, it should be confirmed against the current FDA label and primary literature before being treated as established.

Why these two drugs are prescribed together

Most adults with type 2 diabetes and established cardiovascular disease, or with multiple cardiovascular risk factors, are candidates for both statin therapy and a glucose-lowering drug with demonstrated cardiovascular benefit. The American Diabetes Association's Standards of Care recommends moderate- or high-intensity statin therapy for most adults with type 2 diabetes in the relevant age and risk categories, largely independent of baseline LDL. Empagliflozin carries an FDA indication for reducing the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, based on the EMPA-REG OUTCOME trial. In that trial, a large majority of enrolled participants were already on background statin therapy at baseline, which is the practical reason the two drugs turn up together on so many medication lists. Readers who want the exact statin-use percentage or the precise hazard ratios from EMPA-REG OUTCOME should treat any specific figure quoted online, including in earlier drafts of this article, as requiring verification against the original NEJM publication rather than assuming it is exact.

Metabolism: why the enzyme systems don't collide

Empagliflozin undergoes phase II glucuronidation and, according to its FDA label, is not considered a clinically meaningful inhibitor or inducer of the major cytochrome P450 enzymes at therapeutic doses. Atorvastatin, in contrast, is metabolized substantially through CYP3A4, which is why strong CYP3A4 inhibitors such as certain antibiotics, antifungals, and HIV protease inhibitors can raise atorvastatin levels and increase myopathy risk. Because empagliflozin does not act on CYP3A4 in a clinically relevant way, it does not sit in the category of drugs that change atorvastatin exposure.

There is also limited P-glycoprotein (P-gp) overlap. Empagliflozin is a P-gp substrate, and the FDA label describes only a modest, not clinically relevant, increase in empagliflozin exposure when co-administered with a potent P-gp inhibitor. Atorvastatin does not meaningfully inhibit P-gp at standard doses. Confirm the current label language directly if this detail matters for a specific patient, since label revisions change over time.

Published pharmacokinetic studies from empagliflozin's development program tested co-administration with a range of common medications in healthy volunteers, including other agents used in type 2 diabetes and cardiovascular disease. Where atorvastatin specifically was not one of the tested drugs in a given study, the inference that the interaction profile would resemble that of a mechanistically similar CYP3A4-substrate statin is pharmacologically plausible but is an extrapolation, not a direct finding, and should be labeled as such when cited.

Evidence-status assessment: what is known, plausible, or unverified

Pharmacodynamics: different mechanisms, not competing ones

Empagliflozin lowers blood glucose by blocking sodium-glucose co-transporter 2 in the kidney, producing glycosuria and a mild osmotic diuresis. Atorvastatin lowers LDL cholesterol by inhibiting HMG-CoA reductase in the liver. These are independent mechanisms with no direct pharmacodynamic conflict. Some trial populations receiving SGLT2 inhibitors have shown a small increase in LDL cholesterol, an effect statin therapy is generally able to offset; the exact magnitude reported varies by trial and should be checked against the specific trial publication rather than treated as a fixed number. Empagliflozin's mild diuretic effect and atorvastatin's lack of effect on fluid balance mean there is no established compounding dehydration risk from combining the two.

What real-world and trial evidence supports

Large cardiovascular outcome trials of empagliflozin, including EMPA-REG OUTCOME and the EMPEROR heart failure trials, enrolled populations in which most participants were also on statin therapy, and those trials demonstrated cardiovascular benefit from empagliflozin in that background context. This supports the general clinical practice of using both drug classes together, but it is trial-level evidence about outcomes in mixed populations, not a dedicated interaction study. Observational cohort data comparing SGLT2 inhibitors with other glucose-lowering drugs have also reported lower rates of heart failure hospitalization and death associated with SGLT2 inhibitor use in populations that commonly included statin users. Observational data of this kind can show association but cannot establish that the statin and the SGLT2 inhibitor interact with each other; it mainly shows that using both is common and that the SGLT2 inhibitor's benefit was observed in a statin-treated population. Anyone citing specific hazard ratios from these studies in a clinical document should pull them from the original publication rather than a secondary source.

Monitoring

No laboratory test is established as necessary specifically because a patient is taking empagliflozin and atorvastatin together. Standard monitoring for each drug applies on its own schedule:

• For empagliflozin: baseline and periodic kidney function (eGFR), and clinical attention to signs of ketoacidosis, genital mycotic infection, and volume depletion in at-risk patients, consistent with current FDA labeling.
• For atorvastatin: baseline lipid panel and liver enzymes, with lipid rechecks after initiation or dose changes per guideline-based statin monitoring, and prompt evaluation of unexplained muscle pain or weakness, with creatine kinase testing if myopathy is suspected.

Neither drug's labeling establishes a preferred time of day for the combination; atorvastatin's effectiveness does not depend on dosing time.

When to reassess the regimen

The empagliflozin-atorvastatin combination itself is not the concern in these situations, but the overall regimen may need review:

• A strong CYP3A4 inhibitor is added (for example, clarithromycin or certain antifungals). This is an atorvastatin-and-inhibitor interaction, unrelated to empagliflozin, and may call for a lower atorvastatin dose or a temporary hold per the atorvastatin label.
• Kidney function declines substantially. Empagliflozin's glucose-lowering effect diminishes at low eGFR, though some cardiorenal benefit may persist depending on the indication; atorvastatin does not require renal dose adjustment. This is a reason for the prescriber to reassess empagliflozin's role, not atorvastatin's.
• Diabetic ketoacidosis occurs. Empagliflozin should be withheld during an active DKA episode. Atorvastatin is generally not the drug in question during a DKA workup, but any patient with concurrent rhabdomyolysis or acute hepatic decompensation needs individualized statin management by the treating clinician.

Switching statins

Patients sometimes move from atorvastatin to rosuvastatin or pitavastatin, both of which have less dependence on CYP3A4 than atorvastatin. Because empagliflozin does not meaningfully affect CYP3A4 in the first place, switching statins does not change the empagliflozin interaction picture in either direction. Statin choice in this context is generally driven by LDL targets, tolerability, and other concurrent medications that do inhibit CYP3A4, not by the presence of empagliflozin.

Patient counseling points

• Take both medications as prescribed; there is no established need to separate the doses by time of day.
• Report new muscle pain, unusual weakness, or dark urine, which can signal statin-related myopathy and warrants a creatine kinase check.
• Stay attentive to hydration, particularly during illness, heat, or exercise, given empagliflozin's mild diuretic effect.
• Practice genital hygiene consistent with reducing SGLT2 inhibitor-associated mycotic infection risk.
• Do not stop either medication without talking to the prescriber first, since both drug classes have independent, established benefits in appropriate patients with type 2 diabetes and cardiovascular risk.

Evidence boundary

Established: Empagliflozin and atorvastatin clear through different, non-overlapping hepatic pathways (UGT glucuronidation versus CYP3A4), and neither drug's current FDA label lists the other as a contraindication or dosing precaution. The two drug classes are commonly and appropriately co-prescribed in type 2 diabetes with cardiovascular risk, per current ADA guidance.

Plausible but not directly demonstrated in a dedicated trial pairing these two specific drugs: That the absence of a shared enzyme pathway translates into zero pharmacokinetic effect in every patient population, including those with hepatic or renal impairment where clearance pathways can behave differently than in healthy volunteers.

Not established from the material reviewed here: A published, dedicated pharmacokinetic interaction study specifically pairing empagliflozin with atorvastatin (as opposed to other statins or other comparator drugs), and any single precise numeric figure (percent LDL change, exact hazard ratio, exact co-prescription rate) that has not been checked directly against its original publication.

A note on evidence handling: Several claims in earlier versions of interaction pages like this one (specific hazard ratios, an attributed quotation from a named cardiologist, and an exact LDL percentage) could not be verified against a confirmed primary source in this review and have been removed or narrowed here. Anyone relying on this article for clinical decision-making should confirm current label language and any specific trial statistic directly with the FDA label or the original publication before using it in a patient conversation.